array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(65) "Regeneron shares: Morgan Stanley reiterates buy recommendation ()" ["snippet_en"]=> string(82) "Regeneron shares: Morgan Stanley reiterates buy recommendation () | aktiencheck.de" ["url"]=> string(106) "https://www.aktiencheck.de/news/Artikel-Regeneron_Aktie_Morgan_Stanley_bekraeftigt_Kaufempfehlung-17657988" ["image_url"]=> NULL ["source"]=> string(14) "aktiencheck.de" ["publication_date"]=> string(10) "2024-10-14" ["categories"]=> array(4) { [0]=> string(12) "Stock Market" [1]=> string(14) "Issuing Shares" [2]=> string(18) "General Investment" [3]=> string(16) "Share Repurchase" } } [1]=> array(7) { ["title_en"]=> string(88) "Piper Sandler Maintains Overweight Rating Despite Regeneron Shares Fall By Investing.com" ["snippet_en"]=> string(74) "Piper Sandler Maintains Overweight Rating Despite Regeneron Shares Falling" ["url"]=> string(63) "https://kr.investing.com/news/company-news/article-93CH-1210638" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2024-09-26" ["categories"]=> array(4) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(14) "Issuing Shares" [2]=> string(12) "Stock Market" [3]=> string(16) "Share Repurchase" } } [2]=> array(7) { ["title_en"]=> string(171) "NASDAQ: REGN Lawsuit Against Directors Pending - Investors Who Hold Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Long Should Contact the Shareholders Foundation" ["snippet_en"]=> string(149) "The Shareholders Foundation, Inc. announces that a lawsuit is currently pending by an investor in NASDAQ:REGN shares against certain directors of ..." ["url"]=> string(103) "https://www.newswire.com/news/nasdaq-regn-lawsuit-against-directors-pending-investors-who-hold-22423285" ["image_url"]=> NULL ["source"]=> string(12) "newswire.com" ["publication_date"]=> string(10) "2024-09-11" ["categories"]=> array(12) { [0]=> string(9) "Investors" [1]=> string(24) "Stock Research & Ratings" [2]=> string(10) "Litigation" [3]=> string(21) "Shareholders Feedback" [4]=> string(46) "Management of Legal and Regulatory Environment" [5]=> string(14) "Issuing Shares" [6]=> string(5) "Legal" [7]=> string(12) "Stock Market" [8]=> string(20) "Corporate Governance" [9]=> string(16) "Share Repurchase" [10]=> string(18) "General Investment" [11]=> string(18) "Board Compensation" } } [3]=> array(7) { ["title_en"]=> string(55) "Regeneron shares: What does this mean for the price? ()" ["snippet_en"]=> string(72) "Regeneron shares: What does this mean for the price? () | aktiencheck.de" ["url"]=> string(87) "https://www.aktiencheck.de/news/Artikel-Regeneron_Aktie_Was_bedeutet_fuer_Kurs-16981330" ["image_url"]=> NULL ["source"]=> string(14) "aktiencheck.de" ["publication_date"]=> string(10) "2024-06-01" ["categories"]=> array(5) { [0]=> string(15) "Market Movement" [1]=> string(14) "Issuing Shares" [2]=> string(17) "Commodity Pricing" [3]=> string(12) "Stock Market" [4]=> string(16) "Share Repurchase" } } [4]=> array(7) { ["title_en"]=> string(101) "Vestmark Advisory Solutions Inc. Acquires 164 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(259) "Vestmark Advisory Solutions Inc. increased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 57.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC)." ["url"]=> string(139) "http://www.defenseworld.net/2023/08/18/vestmark-advisory-solutions-inc-acquires-164-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1d072491-7466-4e87-b7e9-ad55a37dee8c" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-08-18" ["categories"]=> array(5) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(11) "Regulations" [2]=> string(14) "Issuing Shares" [3]=> string(11) "Acquisition" [4]=> string(12) "Stock Market" } } [5]=> array(7) { ["title_en"]=> string(87) "Regeneron Shares Jump After Saying It Expects an FDA Decision on Its Eye Treatment Soon" ["snippet_en"]=> string(171) "Shares of Regeneron jumped after the drug maker indicated it expects the FDA will soon approve a higher-dose version of its blockbuster drug to treat macular degeneration." ["url"]=> string(116) "https://www.investopedia.com/regeneron-shares-jump-as-the-firm-expects-an-fda-decision-on-eye-treatment-soon-7569554" ["image_url"]=> NULL ["source"]=> string(16) "investopedia.com" ["publication_date"]=> string(10) "2023-08-03" ["categories"]=> array(3) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(14) "Issuing Shares" [2]=> string(12) "Stock Market" } } [6]=> array(7) { ["title_en"]=> string(111) "Nisa Investment Advisors LLC Has $19.98 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(300) "Nisa Investment Advisors LLC grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 19.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 24,312 shares of the biopharmaceutical compa" ["url"]=> string(76) "https://www.marketbeat.com/instant-alerts/nasdaq-regn-sec-filing-2023-07-21/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/a103b9e3-e9ba-4af2-9a7f-45c1afb663db" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2023-07-22" ["categories"]=> array(7) { [0]=> string(31) "Financial Update/Profit Warning" [1]=> string(12) "Stock Market" [2]=> string(19) "Investment Requests" [3]=> string(18) "General Investment" [4]=> string(14) "Issuing Shares" [5]=> string(11) "Regulations" [6]=> string(24) "Quarterly/Annual Figures" } } [7]=> array(7) { ["title_en"]=> string(110) "Bayer shares continue to fall - buy now because of the favorable valuation or throw them out of the portfolio?" ["snippet_en"]=> string(90) "Bayer shares are in a very important place on the chart. Should investors buy or sell now?" ["url"]=> string(159) "https://www.boerse-online.de/nachrichten/aktien/bayer-aktie-sackt-weiter-ab-jetzt-wegen-guenstiger-bewertung-kaufen-oder-aus-dem-depot-schmeissen-20334657.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/829511e6-4b92-4467-8195-64aae4723f97" ["source"]=> string(16) "boerse-online.de" ["publication_date"]=> string(10) "2023-06-28" ["categories"]=> array(10) { [0]=> string(9) "Investors" [1]=> string(15) "Market Movement" [2]=> string(24) "Stock Research & Ratings" [3]=> string(25) "Business Model Resilience" [4]=> string(9) "Valuation" [5]=> string(14) "Issuing Shares" [6]=> string(11) "Acquisition" [7]=> string(12) "Stock Market" [8]=> string(18) "General Investment" [9]=> string(16) "Share Repurchase" } } [8]=> array(7) { ["title_en"]=> string(84) "D.A. Davidson & CO. Sells 14 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(252) "D.A. Davidson & CO. lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 2.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC)." ["url"]=> string(120) "https://www.defenseworld.net/2023/05/01/d-a-davidson-co-sells-14-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn.html" ["image_url"]=> string(78) "https://images.businessradar.com/articles/c3417438-8e22-4c32-b151-0100da7aa580" ["source"]=> string(16) "defenseworld.net" ["publication_date"]=> string(10) "2023-05-01" ["categories"]=> array(4) { [0]=> string(10) "Divestment" [1]=> string(14) "Issuing Shares" [2]=> string(11) "Acquisition" [3]=> string(12) "Stock Market" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc